Rapid Tests Segmentation
The rapid tests market is segmented by product type, application, end-user, and region. The global need for antibody testing kits to contain the COVID 19 pandemic has created significant growth opportunities in the global rapid testing market owing to soaring confirmed cases that are going beyond control and there is a major shortage of these test kits all across the globe. Many private companies have begun manufacturing rapid test kits to sustain the massive demand.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By Application |
|
|
By End User |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of rapid tests is assessed at USD 1.64 billion.
Rapid Tests Market size was over USD 1.53 billion in 2024 and is projected to reach USD 4.42 billion by 2037, witnessing around 8.5% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to hold largest revenue share by 2037, on account of rising awareness amongst the patients, coupled with high per capita healthcare expenditure, and high widespread presence of target diseases.
The major players in the market are BioMedomics, Altona Diagnostics, Abbott Laboratories, BioMerieux, Roche Diagnostics, Meridian Bioscience, Cepheid, MyLab, Qiagen, AccuBioTech, and others.
